BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. This stock has a reasonable momentum. BioCryst Pharmaceuticals, Inc. has good growth characteristics. BioCryst Pharmaceuticals, Inc. is not very popular among insiders. BioCryst Pharmaceuticals, Inc. is a mediocre stock to choose.

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block...

News

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by Signaturefd LLC

Ticker Report Signaturefd LLC lifted its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 560.5% during the second quarter, according to the company in its most recent disclosure...\n more…

BioCryst Appoints Dr. Donald Fong Chief Medical Officer

Globe Newswire RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Donald S. Fong, MD, MPH, has been appointed as the company's new...\n more…

nVerses Capital LLC Takes Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Ticker Report nVerses Capital LLC acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the...\n more…

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors...\n more…

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $14.17 Consensus PT from Analysts

Zolmax Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat.com...\n more…

Assenagon Asset Management S.A. Has $401,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Ticker Report Assenagon Asset Management S.A. lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 83.2% during the second quarter, according to its most recent filing with the...\n more…